Stephanie San Giovanni
Physician Assistant · Yarmouth Port, MANPI 1568039949
Payments from drug & device makers
Across 86 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$409
- Sumitomo Pharma America, Inc.$340
- Ferring Pharmaceuticals Inc.$175
- 180 Medical, Inc.$161
- Urovant Sciences Inc$161
- Accord Healthcare, Inc.$134
- plus $866 from 18 others
What the payments were for
- Food & beverage$2,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $409 |
| Sumitomo Pharma America, Inc. | 14 | $340 |
| Ferring Pharmaceuticals Inc. | 5 | $175 |
| 180 Medical, Inc. | 7 | $161 |
| Urovant Sciences Inc | 5 | $161 |
| Accord Healthcare, Inc. | 5 | $134 |
| Tolmar, Inc. | 5 | $124 |
| Medtronic | 2 | $110 |
| Boston Scientific | 3 | $98 |
| Antares Pharma, Inc. | 5 | $96 |
| Progenics Pharmaceuticals, Inc. | 3 | $70 |
| Myovant Sciences Inc. | 3 | $63 |
| Immunitybio, Inc. | 2 | $44 |
| Telix Pharmaceuticals | 2 | $39 |
| Bayer | 1 | $35 |
| Johnson & Johnson | 1 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $25 |
| Endo USA, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Pfizer | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Axonics, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$2,245 in reported general payments places this provider in the 90th percentile of 3,507 physician assistant providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 166 | $166,134 |
| MyrbetriqMirabegron | 93 | $91,604 |
| Mirabegron ErMirabegron | 21 | $12,599 |
| ElmironPentosan Polysulfate Sodium | 17 | $12,149 |
| Methenamine Hippurate | 101 | $6,625 |
| Estradiol | 55 | $3,385 |
| Tamsulosin Hcl | 135 | $2,410 |
| Testosterone | 22 | $2,152 |
| Fosfomycin Tromethamine | 12 | $2,001 |
| Trospium Chloride | 25 | $1,762 |
| Solifenacin Succinate | 19 | $1,437 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $903 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 44 | $870 |
| Testosterone Cypionate | 28 | $738 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $340 | $166,134166 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $91,60493 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,507 physician assistant providers in Massachusetts.
Other physician assistant in Yarmouth Port
- Christopher MasseyWilbraham$190K
- Lizabeth O ConnorEverett$182K
- Kimberly ComeauSwampscott$120K
- Stacey PanasciSpringfield$113K
- Jason RandWaltham$99K
- Karen ChunEast Boston$70K
- David PeckhamQuincy$61K
- Leslie SmithSpringfield$49K
- Andrea MilliganBoston$46K
- Lauren RousseauBoston$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.